Explore every episode of the podcast Pharma Market Access Insights - from Petauri Evidence
Dive into the complete episode list for Pharma Market Access Insights - from Petauri Evidence. Each episode is cataloged with detailed descriptions, making it easy to find and explore specific topics. Keep track of all episodes from your favorite podcast and never miss a moment of insightful content.
Discover how data visualisation dashboards can aid field teams in market access discussions with customers.
Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a well-designed, easy-to-use visualisation can build a case for change, while positioning themselves as a trusted partner. Watch this 20-minute discussion between Iain Shield (Associate Director – Market Access) and Ben Spurr (Head of Partnerships) to discover how Connected Insights data visualisation dashboards can help your teams have strategic conversations with healthcare decision-makers. Iain also explains typical use cases for the dashboards for field teams, why data dashboards are useful for the NHS, and what sets Connected Insights dashboards apart.
What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ottawa).
We take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Husereau explore:
The market access landscape in Canada
Upcoming changes at CADTH
What Canadian payers expect from your value proposition
Opportunities and challenges when launching new medicines/medical devices/diagnostics in Canada
How Canada compares to the USA/key European launch markets
What this means for your global market access strategy
Clare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, particularly regarding changes at the Agenzia Italiana del Farmaco (AIFA).
We explore: - The nature of the Italian market and the reimbursement process - Pricing and market access considerations when launching in Italy - What the reforms at AIFA mean for market access and managed entry agreements - How the AIFA changes specifically impact innovative products - Changes to early access programmes in Italy - Impact of these changes on international pricing, particularly with the introduction of the EU Joint Clinical Assessment (JCA)
Dr Farzana Hussain (GP Principal, The Project Surgery) and Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) explore the unmet needs of Primary Care Networks (PCNs) and how industry can best support primary care leaders and GPs as we head into winter, 2024 and beyond.
Former ‘GP of the year’ and strategic influencer over primary care policy, Dr Farzana Hussain, discusses the unmet needs in primary care, how primary care leaders are responding to these challenges, and where industry can best offer support.
Phil and Farzana discuss:
How unmet needs are identified in primary care, the processes followed, and datasets used to inform decision making
The specific challenges facing primary care as we head into winter
The role of PCN leaders and their impact on national policy
How industry can best support and collaborate with PCNs
Ongoing lessons from the pandemic and the vaccine roll-out
How can our community support NHS leaders to deliver a data-led, people-centric health service?
Dr Mark Davies (Global Chief Health Officer, IBM) joins Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) to explore the power of data, the role of community and how the health and life sciences ecosystem can support the NHS’s population health management goals.
Population health management has the potential to be a powerful tool for healthcare systems, effecting the way health and care is strategised, budgeted, targeted, and delivered. We see a future where key decisions in the NHS are driven by population health data. What we now need is a new way of working powered by local need, quality evidence and a systematic approach.
In this webinar, Phil and Mark explore:
- How the NHS can use population health management to transform the system - The importance of community in population health management - How Pharma, Medtech, and the wider life sciences sector can work above brand to support the NHS with population health management - What a data-driven, people-centric approach means for the way treatments are valued - How population health management could transform the economics of healthcare
How is Artificial Intelligence being used in the development of new medicines? What role can AI currently play in clinical trials? Where can AI bridge gaps and solve challenges? What could this mean for the future of market access?
In this webinar, Dr George Magrath explains how his team at Lexitas are using AI in clinical trials in the field of ophthalmology. George and Calum explore:
- How, when and where AI is being used in clinical trials - How Lexitas are using AI in clinical trials for ophthalmology - Where AI may offer solutions to existing obstacles in clinical trials and ophthalmic drug development - What the future holds for AI in the development of new medicines - The role AI can play in selecting patients for clinical trials - The impact AI may have on the way we evaluate drug effectiveness - What this all means for evidence synthesis, health economics, reimbursement and market access - The future prospects of AI in pharmaceutical development
How is the UK political landscape evolving and what does this mean for Health Technology and Medical Device innovators?
Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) speaks to William Lee (Head of Policy and Compliance, British Healthcare Trades Association [BHTA]) about health policy, regulation and its implications for Medtech, Health technologies, and Medical Device market access.
With the challenges of the pandemic and the changes brought in following Brexit, policy and compliance in the UK has been on shifting sands for several years now. With many predicting a change in government at the next election, this continues to be a time of uncertainty. What does this political landscape mean for health policy, the regulatory regime and market access?
In this on-demand webinar, Rob asks Bill about 6 areas where Medtech should be paying attention:
MHRA and new medical device regulatory regime
UK health and social care supply and procurement
Sustainability and social value
Addressing capacity challenges with effective health and social care packages
Here we explore market access challenges in Germany, Austria and Switzerland. Clare Foy (Global Market Access Director – Mtech Access) speaks to Dr Stefan Walzer (CEO, President & Founder at MArS Market Access & Pricing Strategy GmbH) about the challenges and opportunities for reimbursement in the German-speaking markets.
Clare and Stefan discuss: - Preparing for access to Switzerland – a European market outside the EU - Pricing strategy and HTA decision-making in Austria under the new Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) - Launching in Germany – is this still one of the most attractive European markets? - The Financial Stabilisation Act in Germany – what this means for drug pricing
How are nursing professionals supporting the digital evolution in UK healthcare? How can new technologies be leveraged by front-line clinical teams to support improved patient care? And how can Medtech, Digital and Biotech innovators collaborate with the front-line nursing teams in the NHS to drive transformation?
Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) speaks to Jennie Smith, registered nurse, Medtech launch specialist and our new Director of NHS Insight & Interaction at Mtech Access.
Phil and Jennie explore:
- The transformative power of technology in the NHS; particularly on patient pathways - The role of nurses in digital transformation and the adoption and implementation of new technologies - Key nursing champions, including Chief Nurse Information Officers (CNIOs) - How industry can best support the NHS with digital transformation - Our plans to bring together NHS and industry for greater collaboration
In this Global Whispers webinar we explore market access for digital therapeutics. Clare Foy (Global Market Access Director – Mtech Access) speaks to Shefali Shah (Global VP, Market Value and Commercial Effectiveness – MindMaze) about the challenges and opportunities for digital therapies to gain market access and ultimately improve patient outcomes.
In the webinar, Clare asks Shefali about:
The opportunities for digital technologies in neurology and how they may impact existing care pathways in the future
How the digital technology market differs from the pharmaceutical market
Regulatory and reimbursement challenges for digital technologies
Her experiences in launching digital technologies in markets such as the US and Germany
How digital technologies can be used to enhance and complement existing treatments/pathways of care
Lessons other digital health, medical device and pharmaceutical companies can learn from Shefali’s experiences
What does it take to bring a cannabinoid pharmaceutical to market?
We were delighted to welcome Michael Sassano (CEO – SOMAÍ Pharmaceuticals) as the first guest on our new Global Whispers webinar series. Michael shared with us his company’s experiences bringing new products to market, the challenges SOMAÍ Pharmaceuticals have faced and the lessons the Pharma industry can learn from their journey.
In the webinar, Clare asked Michael about: - Drug development and clinical trial processes for medical cannabis products - Differences between the herbal medicines market and the Pharmaceutical market - Overcoming regulatory and reimbursement challenges - Finding the right place for cannabinoid medicines within existing pathways of care - Perceptions, pathways and routes to access in different markets - Lessons for the wider Pharma and Biotech industries
How will changes to the structure of primary care impact decision making? How is the relationship between Integrated Care Boards (ICBs) and primary care stakeholders evolving? How will funding flows be impacted?
Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) is joined by Tim Goodson (Executive Officer, Dorset General Practice Alliance) to explore how primary care is evolving and what this means for decision making, funding, and relationships with industry.
Phil and Tim explore:
The integration journey across primary care
Evolving relationships and structures in primary care in the NHS
Where decisions are made and who makes them
How understanding commissioning priorities and funding flows can help Pharma and Medtech to identify decision makers and understand their needs
Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?
In this webinar, our Global Market Access team compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions, asking: what does this mean for your overarching market access strategy?
Our Global Market Access experts explore contrasting regions to showcase the significant differences between international markets when it comes to:
- Overall and rare disease patient populations - Access inequalities - Time to diagnosis - Access to innovation timelines - Healthcare funding - Health technology assessment frameworks
Robert Taaffe (Consultant – Global Market Access) presents his research into the market access conditions in the MENA regions, with a focus on the rare disease reimbursement landscape in growth markets in Egypt, Saudi Arabia, and the United Arab Emirates.
Michelle James (Associate Consultant – Global Market Access) showcases market access and reimbursement routes in the more established, yet smaller populations in the Nordic regions. Michelle will focus on access in Denmark, Sweden, and Norway.
Clare Foy (Director – Global Market Access) leads our discussion on the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy.
Is data the key to transforming healthcare systems and patient care?
What are the top priorities for digital transformation leaders in the NHS? How can Pharma and Medtech companies partner with the NHS to share data, transform services, and find smarter, faster way to improve patient care?
Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) is joined by Stephen Slough (Chief Digital Information Officer, NHS Dorset) to explore how, through the catalyst of partnership, new technologies and data have the potential to transform healthcare.
We have reached a point where digital is so ubiquitous that, even in the NHS, what were previously seen as ‘digital’ transformation projects are now viewed as simply business transformation projects.
Add in advancements in artificial intelligence and ChatGPT-type services, along with the potential of big data, and it’s no surprise that digital is at the heart of transformation in the NHS.
In this episode, Phil and Stephen explore:
- The digital landscape for NHS decision makers - How, when and where data can transform healthcare systems and patient care - How the NHS and industry can get access to and share our data to better plan products and services - What the top priorities are for digital leaders - How industry build strategic partnerships with Integrated Care Boards (ICBs) and other NHS leaders driving data-led transformation
How and where can innovation drive improvements in care and deliver better health for the population? How is the NHS looking to collaborate with key partners across industry and academia? What innovations are set to transform care? What role do Academic Health Science Networks (AHSNs) play and how can partners best engage with them?
Prof Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) is joined by Bill Gillespie (Chief Executive Officer, Wessex AHSN) to explore innovation in the NHS, the role of AHSNs and the potential for greater collaboration across our sector, in our latest NHS Whispers webinar.
Will NHS leaders, as part of an Integrated Care System (ICS), make conscious decisions to drive economic and social change?
What social and economic value do ICSs offer the wider population they serve? How will industry support ICSs to deliver population-based health and social benefits?
Prof Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) is joined by Michael Wood (Head of Health Economic Partnerships, NHS Confed) for a far-reaching discussion around system integration, population health management, and the NHS’s social and economic potential.
In December (2022), Michael Wood authored a report exploring one of the four key purposes of an ICS: to help the NHS support broader social and economic development. Michael’s NHS Confed report looked at the economics of healthcare and where broader strategic partnership working might lead system thinking in the NHS.
Phil Richardson was one of several experienced ICS, local authority, university and professional experts that Michael invited to share their perspectives in the report.
We were delighted to bring Michael and Phil together in this webinar to discuss these topics, particularly in light of what these new leadership purposes mean for the NHS’s relationship with the Pharmaceutical and wider Life Science industries.
In the webinar, Phil and Michael discuss:
NHS Confed and the links between the health sector and the economy
The need for ICS leaders to focus on broader social and economic development
How Pharma and Medical Device companies can add value to support this key ICS purpose
Why health and economic development is key to tackling health inequalities
The important role the NHS plays as an anchor institution that links better health with economic and social development
What health and economic development could mean for funding at different levels of an integrated system – e.g. place based commissioning
Opportunities for industry to step up and support the NHS with economic and social development
The proposed new NHSE systems for specialised commissioning are arguably the highest risk of all current dynamics, both for the NHS and for suppliers. Key aspects or policy have been published in ways that are hard to access and even harder to interpret. Here, we gather an expert panel to discuss what proposed new NHSE systems for specialised commissioning mean in practice.
In this episode, we explore: - What’s new for Specialised Commissioning and what’s set to change? - What are the potential implications of the proposed changes recently published? - Integrated Care Boards (ICBs) and their increasing role with Specialised Commissioning - What this means for the NHS and for industry in practice
The episode begins with an overview and analysis of the changes from David Thorne (Principal Associate, Mtech Access and Business Development Director, Well Up North PCN). David then opens up a broader discussion about the implications of these changes with our guest panellists James Curtis (Deputy Operational Director, Gloucestershire NHS Foundation Trust) and Mohammed Asghar (ICS Prescribing Governance Lead at Frimley Health and Care ICS).
With so many patients left waiting for NHS care, what will the long-term impact be? How can Pharma and Medtech support the NHS with systematic challenges, like waiting? Where can industry work with the NHS to improve patient flow to get people appropriate treatment sooner and limit the harm caused by waiting? Prof Phil Richardson (new Chief Innovation Officer, Mtech Access and until recently, Executive Director at NHS Dorset ICS) joins Tom Clarke (Director, Mtech Access) explored all this and more.
In this NHS Whispers webinar, we explore:
- The pressures facing NHS systems and how this results in patients waiting - The long-term impact of this waiting; what it means for patients, their - outcomes and treatment - What informs how NHS system leaders identify and approach these challenges - How health and care systems can make effective decisions in this climate - How Pharma and Medtech can support system leaders with these challenges
This webinar was first broadcast as a live webinar in November 2022. Learn more.
How is the NHS balancing competing challenges as we head through integration and towards winter? How are priorities set and what does system planning look like in primary care?
Dr Alex Degan (Primary Care Medical Director, Devon Integrated Care System [ICS]) joins Tom Clarke (Director, Mtech Access) to explore all this and more.
In this episode, we explore how primary care leaders are reacting to the ongoing changes and challenges facing the NHS. Tom Clarke interviews primary care leader Alex Degan to explore:
How priorities are set and what is driving change
What system planning looks like in primary care
The impact of integration – now in practice and for future planning
How Pharma and Medtech can best support primary care
On 1st July we saw the introduction of legislation for Integrated Care Systems (ICSs) in the NHS. In the weeks since, what has changed for healthcare leaders, practitioners and patients? What are the key priorities for NHS decision-makers and what is getting in the way of change? How can Pharma and Medtech support their NHS customers as they implement this change?
In this episode Tom Clarke (Director, Mtech Access) explored all this and more with Steve Reed (Head of Community Services, York Teaching Hospital NHS FT) and Dr Viren Mehta (Vice Chair, Viaduct Care and Clinical Director, Cheadle Primary Care Network).
Together, they explore:
What integrated care really means in practice
How integrated the NHS really is at the moment
What the key priorities are for those driving integration and leading ICSs
What is getting in the way of change, and how industry can help
What roles and responsibilities do Clinical Pharmacists have in the NHS? How can Pharma and Medtech engage Clinical Pharmacists, and how can industry best support these new decision-makers?
Tom Clarke (Director, Mtech Access) explores all this and more with Tom Kallis (Senior Clinical Pharmacist, East Cornwall PCN).
They explore the origins of the Clinical Pharmacist role and how it has become a key part of the primary care landscape, to understand how the responsibilities of those in the role have been growing. They discuss examples of specific, surprising, ways in which Clinical Pharmacists are expanding their skillsets and doing far more than just medicines use reviews and signing off prescriptions.
As the NHS takes steps towards a more integrated future, how are systems and care pathways transforming? How is change being implemented, and what does this look like in reality for local systems and populations?
Tom Clarke (Director, Mtech Access) explores all this and more with Debbie Morgan, (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Foundation Trust).
In this #WhispersWordsofWisdom webinar, Tom and Debbie explore the reality of transforming systems and care pathways in an NHS that’s moving towards an integrated future, asking:
What does change look like for patients and their care pathways?
How are systems changing, and how will decisions be made and implemented?
What does this mean for Pharma and Medtech market access and industry’s engagement with the NHS?
To understand how systems are approaching change, Debbie and Tom explore areas such as the elective recovery programme, virtual wards, and local population needs.
As Director of Service Improvement and Transformation at Cambridge University Hospitals NHS Foundation Trust, Debbie leads the Trust’s improvement programme; engaging and empowering staff and patients on the journey of improvement and sustainability. She has previously held roles as Director of Commissioning and Head of Corporate Management at the Trust. Debbie originally joined the NHS in 1993 as a Clinical Cytogeneticist, before moving into NHS management in 2011. She has undertaken a wide variety of roles over the years, including commissioning and service improvement across the local health system, and has worked at director level for over 9 years.
Our experts in health economics, value communication, design and digital discuss how to craft digital payer value communication tools to meet the needs of internal stakeholders, including market access teams and KAMs, and healthcare customers.
What does a best-in-class value communication tool look like in 2022? What are the key considerations when developing a new payer value toolkit? And what should Pharma and Medtech companies look for in a consultancy partner?
Using our updated Digital Value Communication Tool Demo as a case study, our panellists explained how we craft our tools to meet the needs of three key groups:
Those who commission the tools – e.g. market access, brand and commercial leaders
The end-users – e.g. key account managers
The audience – e.g. payers and other healthcare decision-makers
This podcast was originally recorded as a live webinar. The webinar featured a run through of our new demo interactive budget impact model and and value proposition tool. This section has been cut from the podcast recording as it is highly visual. Click here to see the demo video or visit our demo centre to explore the demo yourself. We'd love to show you more - email info@mtechaccess.co.uk to arrange a more detailed demo and discussion meeting.
Which decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders?
We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion that explored finance, funding flows, system priorities, and the decision-making process in NHS Regions.
Richard heads up system co-ordination work across the NHS South West Region. The Region has seven Integrated Care Boards (ICBs), 22 Trusts, nine counties and a resident population of over 5.5 million patients stretching from Gloucestershire and Wiltshire to the Isles of Scilly.
The interview was led by David Thorne (Principal Consultant, Mtech Access and Transformation Director at Well Up North Primary Care Network [PCN]) who put both the NHS and industry perspectives to Richard to explore the real state of the NHS.
In this episode, David and Richard discuss: - Where the NHS is heading and what this means for your strategy and business planning - Decision making, finances, and funding flows across the NHS - The role of NHS Regions, particularly with key funding decisions like Specialised Commissioning - Delivering service change across integrated systems - Policy priorities in practice and what to expect in an election year - How Pharma, Medtech, and Diagnostics companies can best engage NHS leaders at Region level
What does population health management mean for the NHS, for patients, and for industry? How will the NHS translate population health management into impactful service change and what will this look like for patients?
Tom Clarke (Director, Mtech Access) explores all this and more with guest speaker Dr Steven Laitner (GP, Parkbury House Surgery). Steven and Tom explore how the NHS can translate the theory of population health management into practical service changes that improve care for patients. They consider the role data will play, the challenges of limited data and whether a busy and tired health service can utilise population health data effectively. They also consider where and how Pharmaceutical and Medtech companies can support the NHS with population health management and service improvement.
What does the ‘2022/23 priorities and operational planning guidance’ document mean for the NHS, for Integrated Care System (ICS) development and for an NHS workforce still battling COVID? How realistic and achievable are the priorities set out, and how can Pharma and Medtech best help NHS leaders to achieve these goals?
Caroline Dawe (Deputy Director of Commissioning, Bristol, North Somerset and South Gloucestershire Clinical Commissioning Group [CCG]) joins Tom Clarke (Director, Mtech Access) to explore all this and more.
Pharma and Medtech professionals put questions to our panel of NHS associates as we reflected on the operational, structural, and clinical challenges the NHS has faced in 2021 and how Pharma and Medtech can best support the NHS in 2022.
We were joined by some of Mtech Access’s closest and most insightful friends:
- David Thorne (Director, Mtech Access and Well Up North PCN) our Policy expert - Patrick McGinley (Head of Costing and Service Line Reporting, Maidstone and Tunbridge Wells NHS Trust) our Hospitals and Finance expert - Liz Cross (Advanced Nurse Practitioner, Attenborough Surgery, Watford) our Primary Care and Clinical expert - Ewan Maule (Interim Chief Pharmacist, North East and North Cumbria ICS) our System and Medicines expert
How will medicines be valued in the newly integrated world of the NHS? What are the risks and benefits of a single national formulary? What else is changing? And what does this mean for market access?
Ellen Rule (Programme Director of the Gloucestershire Integrated Care System [ICS] and Director of Transformation and Service Redesign, Gloucestershire Clinical Commissioning Group [CCG]) joins Tom Clarke (Director, Mtech Access) to explore all this and more.
The risks and benefits of a single national formulary and what this means for market access
How to support system and local networks to implement pan-ICS approaches to medicines optimisation
How industry can distinguish their product in this new world where systems become automated to substitute generics and biosimilars for branded medicines
Ellen and Tom discussed the implications of this paper, and the broader context of value in integrated care.
We explore the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe.
Orphan medicines and rare disease treatments are faced with a complex, ever-changing market landscape. These treatments also face unique tactical challenges on the route to securing market access.
Current and future market events and trends for rare disease products across Europe
Clinical evidence development, including tactical challenges around evidence generation and how to address these
Building the health economic case, including key principles and tactical nuances for health economic modelling in rare and orphan disease
This podcast was originally broadcast as a live webinar on 17th November 2021. To learn more and request a copy of the slides used please visit our website.
A new paradigm for the NHS: Partnering to deliver lasting and meaningful care improvements - with Dr Phil Webb (Chief Executive of Respiratory Innovation Wales)
How are healthcare systems looking differently at their population to deliver better care and what does this mean for future decision-making? How might the NHS re-imagine the hospital? What benefits can we expect from novel technologies, and can the NHS develop system resilience to improve healthcare outcomes?
Dr Phil Webb (Chief Executive of Respiratory Innovation Wales) joined Tom Clarke (Director, Mtech Access) to explore all this and more. Re-imagining the hospital, investing in novel technologies, and developing system resilience to improve healthcare outcomes were all discussed. This episode also explores specific examples of how the Welsh Healthcare System is pushing itself to better care for the people it serves and where the obstacles to delivering change lie.
As Chief Executive of Respiratory Innovation Wales, Phil has a remit for re-imagining care for people across Wales. He previously held roles within the Welsh Healthcare System responsible for Innovation and Service Development, and has commissioned services at national and local levels. Also having worked in Industry, Phil’s academic background includes health economics, epidemiology, statistics, and a doctorate in molecular biology.
As such, we were interested to hear Phil’s perspective on everything from driving innovation in the NHS to the obstacles facing NHS systems, and how Pharma and Medtech can best help. This webinar is a must-see for anyone with an interest in how care systems are evolving further and faster than we could imagine, not just in Wales and respiratory care, but across all clinical and geographic areas.
This episode was originally broadcast as a live webinar on Friday 17th September 2021.
How can the NHS address health inequalities through innovation? How can new health technologies help improve population health? How can Pharma, Medtech and the wider life sciences industry support the NHS with these goals? And what does the NHS’ ambitions in this area mean for your market access strategy?
Jon Siddall (Chief Executive of the South West Academic Health Science Network [AHSN]) joins Tom Clarke (Director, Mtech Access) to explore these questions and more.
Before joining the South West AHSN as CEO in April 2020, Jon spent 3 years as the director of funding at Guy’s and St Thomas’ Charity, where he led the design and development of the foundation’s £150 million portfolio of urban health programmes focused on some of the biggest health challenges facing cities around the world. During his career Jon has worked with funders, investors and government agencies in the UK, Ireland and New Zealand. His work included 4 years at the South West AHSN, helping to launch the organisation and developing a range of successful innovation programmes.
What role do Ambulance Trusts play in the success of the wider NHS? How might urgent and community care evolve as we head to integration as part of a joined-up system? How will an integrated ambulance service support system redesign to keep people out of hospital, and provide more proactive care to those who need it most?
Helen Ray (Chief Executive of North East Ambulance Service NHS Foundation Trust) joins Tom Clarke (Director, Mtech Access) to discuss the role Ambulance Trusts play in delivering care. This role far exceeds attending 999 calls. We explored the important role Ambulance Trusts play in keeping people out of hospital and in instigating new models of care. They are the first point of contact for many clinical events, both on the ground and through their role in NHS 111.
As such, Ambulance Trusts understand first-hand the real drivers for accessing health services. Helen Ray, as Chief Executive of North East Ambulance Service NHS Foundation Trust is ideally placed to open a window to their world and explore what a more integrated future may mean for emergency care and the wider health system.
Helen Ray joined North East Ambulance Service in 2019, following 36 years’ experience in various roles across the NHS. Helen was previously Chief Operating Officer at Northumbria Healthcare NHS Foundation Trust, where she oversaw urgent and emergency care, medicine, child health, and community services with Board level responsibility and emergency planning and preparedness. She has also previously been Joint Managing Executive Director (operations) for North Cumbria acute and community services; Deputy Chief Executive for North Cumbria University Hospitals; and Chief Operating Officer for South Tyneside NHS Foundation Trust. She trained as a nurse and has held a professional registration for 30 years.
This episode was first broadcast as a live webinar on Friday 25th June 2021.
Population health management is often talked about in top-down terms, but how seriously will the needs of individuals be taken as systems develop? How will personal needs inform care delivery? Why will the patient voice play a very different role in the NHS of the future?
Steph Edusei (Chief Executive of St Oswald’s Hospice) joins Tom Clarke (Director, Mtech Access) to explore these questions and more.
This episode was first released as a live webinar on Friday 21st May 2021.
Steph Edusei has held the role of Chief Executive at St Oswald’s Hospice since May 2020. The hospice provides specialist care for adults, babies, children and young adults from across the North East of England and takes a proactive approach to integrated care, working with other NHS providers in the region and the wider population.
Prior to this, Steph was Chief Executive of Tell us North, the organisation that run Healthwatch Newcastle and Healthwatch Gateshead, giving her extensive experience in local healthcare and how this integrates with wider NHS systems. She has also held a wide variety of leadership and senior operational positions, including Interim Deputy Chief Executive at Newcastle Council for Voluntary Services; Authorisation Development lead and then Strategic Head of Corporate Affairs at NHS Northumberland Clinical Commissioning Group (CCG); Assistant Director, Commissioning at NHS North of Tyne, and Assistant Director of Operations at North East Ambulance Service NHS Trust. Rarely does one come across an individual with such a breadth of experience across so many different services supporting population health.
What will a ‘Place’ look like? What will this new layer of the NHS mean in practice and what decision-making powers will Place leaders have?
As the NHS starts its journey towards an integrated future, Dr Steven Michael OBE (Chair of East Cheshire Partnership) joins Tom Clarke (Director, Mtech Access) to talk ‘Place’, ‘Partnership’, ’Collaboratives’ and more.
The UK Government’s Health and Care White Paper, along with other recent policy announcements, set out a major proposed reorganisation of the NHS in England. This includes the introduction of the term ‘Place’, a localised function within Integrated Care Systems (ICSs). There is still much uncertainty, even within the NHS, about what this term and others like ‘Collaborative’ will mean in practice.
In this episode, Tom and Steven discuss what these new structures mean, how they may affect the patient experience, how they will impact decision-making and what they could mean for pharmaceutical and medtech market access.
Dr Steven Michael OBE has over 20 years of experience in the NHS. He began his career as a registered nurse working in psychiatric intensive care in 1985, before rising through various management and leadership roles to be CEO of a South West Yorkshire Partnership NHS FT between 2007 and 2016. He has since contributed to or chaired a number of NHS boards, including the NHS Confederation’s Mental Health Network, Spectrum Community Health CIC and East Cheshire Partnership.
This episode was first broadcast as a live webinar on 30th April 2021.
What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation?
Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by guest speakers Debbie Morgan (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Foundation Trust), Ellen Rule (Deputy CEO/Director of Strategy & Transformation, Gloucestershire Integrated Care Board) and Dr Viren Mehta (GP Partner, GP Federation Chief Officer, Viaduct Care). Together we explored what all this uncertainty means for NHS decision-making, day-to-day operations, strategy, and engagement with industry.
In this webinar, we bring together leaders from across the NHS to explore how they are planning and operating in this uncertainty.
We explore: - Strategy and planning in these times of uncertainty - What’s happening with GP contracts - Financial pressures and challenges - If/where it’s possible to drive forward change in the current environment - How Pharma and Medtech can best support NHS leaders - Where the panel would welcome solutions from industry
Please note this episode was first broadcast in January 2024 as a live webinar. Some aspects of policy discussed have evolved and continue to evolve.
Are you looking to launch a new medical technology, medical or diagnostic device in the UK, Europe or North America? Would you like to know how health economic modelling could support your market access journey?
In this episode, converted from a recent live webinar, Calum Jones (Consultant Health Economist) and Nick Swart (Senior Health Economist) discuss what, why and how health economic models can support MedTech innovations to demonstrate value, achieve market access and reach more patients.
Health economic modelling is becoming a key component of the MedTech market access journey. There is increasing need in many countries to demonstrate economic evidence for new technologies, with many health technology assessment (HTA) bodies now requiring economic models before offering guidance for reimbursement, such as NICE’s Medical Technology Evaluation Programme (MTEP). MedTech firms are also recognising that a cost effectiveness model can also offer robust evidence of interventional value to support discussions with payers and other healthcare stakeholders.
In this episode, Calum and Nick share their complementary perspectives and experiences of helping MedTech companies achieve market access.
Please email info@mtechaccess.co.uk for a copy of Calum and Nick's slides or to find out more about how Mtech Access can support your market access journey.
What changes can we expect to pharmacy, medicines management, and specialised commissioning in the new NHS? Professor Inderjit Singh (Chief Pharmacist at University Hospitals Birmingham) joins Tom Clarke (Director, Mtech Access) to explore all this and more.
Professor Singh is one of the leading pharmacists in today’s NHS and is currently Chief Pharmacist at University Hospitals Birmingham NHS Foundation Trust. He has responsibility for the provision of the pharmacy service within the Trust and for ensuring appropriate governance of medicines. He provides strategic oversight into commercial pharmacy matters and strategic support to Heath Trust Europe, a collaborative procurement hub based in Birmingham.
This episode was first broadcast as a live webinar on Friday 26th March 2021.
Are you wondering what integrated care will look like when the Health and Care White Paper proposals become a reality? Tom Clarke interviews Dr John Ribchester about what the proposals means in practice for clinicians, for patients and for the life sciences industry.
Dr Ribchester is a GP and Clinical Director of Whitstable Primary Care Network (PCN) in Kent and has led development of an integrated service that represents many of the desired endpoints of the White Paper changes.
This episode was first broadcast as a live webinar on Friday 26th February 2021 as part of our #WhispersWordsofWisdom series. The original broadcast has been edited for clarity.
Heads at the heart of the NHS: How mental health is central to everything in the new NHS - with Brent Kilmurray (Chief Executive of Tees, Esk and Wear Valleys NHS Foundation Trust)
With mental health services facing unique challenges, Brent Kilmurray (Chief Executive of Tees, Esk and Wear Valleys NHS Foundation Trust), joins Tom Clarke (Director, Mtech Access) to explore the challenges of leading mental health services in the NHS.
As Chief Executive of the Tees, Esk and Wear Valleys NHS Foundation Trust, and with almost 20 years of experience in strategic and operational roles in the NHS, Brent is well placed to explore the challenges facing mental health services and what can be done to deliver change in this area.
The Tees, Esk and Wear Valleys NHS Foundation Trust provides a range of mental health, learning disability and eating disorder services for the people living in County Durham and Darlington, the Tees Valley and most of North Yorkshire.
This recording was first broadcast as a live webinar on 29th January 2021 as part of our #WhispersWordsofWisdom series.
With new policy passing power to Integrated Care Systems (ICS), we explore how pharmacy and medicines commissioning will work in the new system, with Laura Angus (Interim Lead Pharmacist, Humber, Coast and Vale ICS)
In our December #WhispersWordsofWisdom webinar, Tom Clarke was joined by Laura Angus who, in her new appointment as a Lead Pharmacist in an Integrated Care System (ICS), is currently evaluating the impact of the transfers of budget and decision-making power from Clinical Commissioning Groups (CCGs) to an ICS. Her appointment as Interim Lead Pharmacist at Humber Coast and Vale ICS in November, follows 7-years as Head of Prescribing at NHS Vale of York CCG.
Laura shares her frontline insights into the structural changes in the NHS, and what this means for pharmacy and the role of medicines.
This episode was originally broadcast on 15th December 2020 as a webinar.
Dr Peter Brambleby (Independent Public Health Consultant) joins Tom Clarke (Director, Mtech Access) to discuss the role public health has played through the COVID pandemic and its importance to the population going forward.
This webinar forms part of our monthly Whispers’ Words of Wisdom series, in which we have in‑depth, comprehensive conversations with senior colleagues from the NHS. We explore what their immediate priorities are, what they see as the greatest challenges faced by the NHS, and how the NHS might respond to these challenges.
We were delighted to welcome Peter to the #WhispersWordsofWisdom series.
This episode was originally broadcast on 13th November 2020 as a webinar.
Simon Parsons (Divisional Director of Surgery at Nottingham University Hospitals NHS Trust) joins Tom Clarke (Director, Mtech Access) to discuss how decisions, such as the postponement of non-urgent elective surgery, are made, the impact this has on patients and staff, and how the NHS might adapt to provide care for these patients.
In addition to his role as Divisional Director of Surgery at Nottingham University Hospitals NHS Trust, Simon Parsons is a Consultant Oesophago Gastric Surgeon. He works as part of the team of gastro-oesophageal surgeons in Nottingham carrying out a full range of cancer surgery on the stomach and oesophagus.
As Divisional Director, Simon is passionate about transformation of surgical services and believes technology plays a pivotal role in this transformation.
Simon is also a director of EIDO Healthcare Ltd., a company specialising in information for informed consent. EIDO has used technology to transform the way it delivers its services.
We were delighted to welcome Simon to the #WhispersWordsofWisdom series.
This podcast was first recorded as a video on 23rd October 2020.
Discover what it’s like to be a leader in today’s NHS and how industry can best support NHS leaders. Deborah Lee (Chief Executive of Gloucestershire Hospitals NHS Trust) speaks to David Thorne (Director, Mtech Access) about how she and her colleagues are responding to the challenges presented by the COVID-19 pandemic, the resultant backlog in care, and the latest policy changes.
Deborah Lee has held the role of Chief Executive at Gloucestershire Hospitals NHS Trust since 2016. Prior to this she was Deputy Chief Executive and Chief Operating Officer at United Hospitals NHS Trust in Bristol. Deborah has also held board level and other senior roles in NHS commissioning organisations and primary care.
Deborah has twice made the Top 50 NHS Chief Executives list and has been nationally recognised by the Health Service Journal as one of the Top 50 Inspirational Women in Healthcare.
This episode was originally broadcast on 25th September 2020 as a webinar.
Dr Claire Fuller (Senior Responsible Officer at Surrey Heartlands Health and Care Partnership) joins Tom Clarke(Director, Mtech Access) to discuss the evolving world of Integrated Care Systems (ICS).
As Senior Responsible Officer for Surrey Heartlands Health and Care Partnership, Dr Fuller leads the delivery of plans to transform care for a population of over 850,000 people. Her role sees her collaborate with hospital, community, and primary care partners to introduce innovations that improve patient care.
A practicing GP since 1995, Dr Fuller’s perspective on the NHS stretches from the frontline of care delivery right through to national policy. Dr Fuller currently chairs the national RightCare Clinical Group and is a member on the national RightCare Oversight Group.
We are delighted to welcome Dr Fuller to our Podcast.
This episode was originally broadcast on 28th August 2020 as a webinar.
From capacity management to changing performance measures, discover what’s changing in the NHS, the impact on the NHS long-term plan and what all this means for the future of market access. Tom Clarke and David Thorne, from the Mtech Access NHS Insights & Interaction team, review some of the insights from our earlier series: ‘How is COVID-19 impacting the NHS?’, as well as exploring trends and challenges uncovered in conversation with our network of NHS Associates in our first 'Whispers Words of Wisdom' podcast.
Tom and David begin by reflecting on what has changed in the NHS over 2020 and how this has evolved over time. They explore how the NHS response to the pandemic has impacted long-term plan priorities, particularly in the light of the recently published Evidence Based Interventions Engagement document (from http://www.aomrc.org.uk/ebi/).
Tom and David also discuss cooperation, collaboration and capacity management both within the NHS and with the independent sector. They consider how quickly hospitals and primary care will be able to clear the backlog of patients and the measures that might be brought in to enable this.
Taking all of this into consideration, David and Tom discuss how the pharma and medtech industries can support the NHS at this time and how these changes may impact the future of market access. For example, they explore how changes to performance measures may affect future economic models and how economic evaluations could be made more relevant to local commissioning decisions.
This episode was originally broadcast on 31st July 2020 as a webinar.
What is health economic evaluation and which modelling approaches can be used to support market access activities?
In this episode, our expert health economists explain the key strengths and limitations of the most common health economic modelling classifications and structures. Here, Hannah Gillies (Consultant – Health Economics) and Daniel MacDonald (Associate Consultant – Health Economics) de-mystify the different approaches to health economic modelling.
Our specialists explore six of the most common health economic modelling structures used to support market access activities; - Decision trees - Markov models - Semi-Markov models - Partitioned survival models - Cox regression models - Discrete event simulations
This episode was first broadcast as a live webinar in January 2024. For more information or to request a copy of the slides used, please visit: https://mtechaccess.co.uk/de-mystifying-health-economic-models/
Work with our health economists: https://mtechaccess.co.uk/health-economics/
We are joined by Jim Easton (CEO of Care UK) to discuss the role of the independent sector in supporting the NHS and the wider care industry, both during the pandemic and in a post-COVID world.
In this COVID-19 series, Tom Clarke (Director - NHS Insights & Interaction, Mtech Access) is joined by NHS and other UK healthcare experts who offer real-world, first-hand insight into the challenges facing the NHS and explore the implications for market access, brand and HCP-facing teams, in pharmaceutical and medical device companies.
In this episode, Tom asks Jim: - How has the private sector responded to COVID? - What have been the biggest challenges/risks in private provision? - What has been the impact of COVID on public-private relationships and collaboration? - How important is the private sector going forward, and in which service/therapy areas? - What does the future hold for independent providers?
This episode was originally broadcast on 19th June 2020 as a webinar. This podcast series has been converted from our webinar series 'How is COVID-19 impacting the NHS?'.
We explore a different aspect of the COVID response, speaking with Stephen Bourke (Co-Founder of Echo), to learn how Echo and other tech companies have been supporting patients with new ways of accessing healthcare, throughout lockdown.
In this COVID-19 series, Tom Clarke (Director - NHS Insights & Interaction, Mtech Access) is joined by NHS and other UK healthcare experts who offer real-world, first-hand insight into the challenges facing the NHS and explore the implications for market access, brand and HCP-facing teams, in pharmaceutical and medical device companies.
In this episode, Tom asked Stephen: - Can you briefly outline Echo’s origins and purpose? - How soon did you sense that Echo would have a key role to play in the national COVID response? - Can you talk us through the impact the pandemic has had on Echo, in terms of your need to upscale and respond? - What have you noticed about the Echo patients population? – numbers, demographics, behaviours, etc? - What have you noticed in other areas of health tech through this period? - We have heard from many NHS colleagues that this is a ‘tipping point’ in care delivery, do you sense that for Echo and digital healthcare? - What needs to happen to embed the positive behaviours and technologies in ‘the new normal’? - What are the risks to digital healthcare in a post-Covid world? - What advice would you give to anyone looking to design or implement digital health innovation?
This episode was originally broadcast on 12th June 2020 as a webinar. This podcast series has been converted from our webinar series 'How is COVID-19 impacting the NHS?'.
In this 'Questions Time' special we welcome a broad panel of practitioners from across the NHS to explore the themes of care delivery, collaboration, innovation and governance. Our panellists are:
Cameron Ward (Interim Director of Strategy and Outcomes, Sefton CCG)
Hilary Snowdon (Management Lead, West Northumberland PCN)
Patrick McGinley (Head of Costing & SLR, Maidstone & Tunbridge Wells NHS Trust)
Dr Su McCole (GP & Area Clinical Director)
This episode is part of our COVID-19 series, where Tom Clarke (Director - NHS Insights & Interaction, Mtech Access) asks experts holding operational, strategic and clinical roles across the NHS to share their experiences and insights into how the NHS has responded to COVID-19 and the wider challenges facing the health service.
In this special 1-hour episode, our panellists explore:
Care delivery:
What will happen to elective procedures over the next few months - how will they be prioritised & delivered?
How will services begin to mobilise themselves while the threat of a second (and subsequent) wave remains?
Collaboration:
What are the highlights you have seen locally in approaches to collaborative working?
Do you think trust has been built in partnership working that will continue post COVID, both within the NHS and with external partners?
What has been your experience of working with the pharmaceutical industry during this COVID pandemic?
Innovation:
How will innovations that have happened during COVID be evaluated so the best ones are kept?
What elements of the remote care used, evolved or developed during the pandemic will become standard elements of NHS care, and in what time frame?
What risks are attached with the innovations we have seen during COVID?
Governance:
What lasting ‘relaxation’ effects on NHS governance (engagement; medicine trials; budgets etc.) do you anticipate as remaining post pandemic?
What part do you expect the NHS to play in covering the ‘COVID bill’ that the country has been left with?
This episode was originally broadcast on 5th June 2020 as a webinar. This podcast series has been converted from our webinar series 'How is COVID-19 impacting the NHS?'.
The Changing Face of Care Delivery Part 2: The Primary Care & Community View with Steve Reed (Head of Community Services, York Teaching Hospitals NHS FT) and Dr John Ribchester (PCN Clinical Director, GP and Chair of Encompass GP Partnership, Whitstable)
With Steve Reed (Head of Community Services, York Teaching Hospitals NHS FT) and Dr John Ribchester (PCN Clinical Director, GP and Chair of Encompass GP Partnership, Whitstable, Kent) as our guides, we revisit the changing face of care delivery, this time from the viewpoint of primary care and the community. Steve and John give us their perspectives on out of hospital care and how it has been transformed during the pandemic.
In this COVID-19 series, Tom Clarke (Director - NHS Insights & Interaction, Mtech Access) asks experts holding operational, strategic and clinical roles across the NHS to share their experiences and insights into how the NHS has responded to COVID-19 and the wider challenges facing the health service.
Tom begins by asking John to describe how primary care has changed since COVID-19 hit our shores in the UK, and the context of the pace of change for general practice. Tom then asks Steve to explain how he had been developing community services before COVID and the impact the pandemic has had on this agenda. Steve discusses how community services could change going forward and what role his teams could play for patients in the future. Tom then asks John about whether this could be a tipping point for primary care in terms of its scope and purpose, and what the most profound lasting changes could be.
This episode was originally broadcast on 29th May 2020 as a webinar. This podcast series has been converted from our webinar series 'How is COVID-19 impacting the NHS?'.